[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Compass Therapeutics Inc (CMPX)

Compass Therapeutics Inc (CMPX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 363,778
  • Shares Outstanding, K 180,088
  • Annual Sales, $ 0 K
  • Annual Income, $ -66,490 K
  • EBIT $ -75 M
  • EBITDA $ -75 M
  • 60-Month Beta 0.89
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.98

Options Overview Details

View History
  • Implied Volatility 111.32% (+8.19%)
  • Historical Volatility 62.18%
  • IV Percentile 11%
  • IV Rank 3.94%
  • IV High 895.68% on 01/21/26
  • IV Low 79.11% on 08/13/25
  • Expected Move (DTE 28) 0.37 (18.09%)
  • Put/Call Vol Ratio 0.10
  • Today's Volume 692
  • Volume Avg (30-Day) 1,030
  • Put/Call OI Ratio 0.47
  • Today's Open Interest 39,673
  • Open Int (30-Day) 38,909
  • Expected Range 1.65 to 2.39

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 16 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.10
  • Number of Estimates 7
  • High Estimate $-0.09
  • Low Estimate $-0.11
  • Prior Year $-0.14
  • Growth Rate Est. (year over year) +28.57%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.75 +15.39%
on 05/19/26
2.47 -18.22%
on 05/29/26
+0.19 (+10.38%)
since 05/18/26
3-Month
1.61 +25.47%
on 04/27/26
6.84 -70.49%
on 04/16/26
-3.30 (-62.03%)
since 03/18/26
52-Week
1.61 +25.47%
on 04/27/26
6.88 -70.64%
on 02/03/26
-0.36 (-15.13%)
since 06/18/25

Most Recent Stories

More News
Compass Therapeutics Eyes FDA Path After Tovecimig Trial Win

Compass Therapeutics (NASDAQ:CMPX) Chief Executive Officer Tom Schuetz said the company is preparing for a key U.S. Food and Drug Administration meeting on tovecimig, its DLL4/VEGF bispecific antibody,...

CMPX : 2.02 (-1.46%)
Compass Therapeutics to Participate in Upcoming June Investor Events

BOSTON, May 28, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to...

CMPX : 2.02 (-1.46%)
Compass Therapeutics to Present Promising Phase 1 Clinical Data for CTX-8371 in Patients with Advanced Malignancies Treated in the Post-Checkpoint Inhibitor Setting at the 2026 ASCO Annual Meeting

CTX-8371, a novel dual checkpoint blocker that simultaneously targets the programmed death receptor PD-1 and its ligand PD-L1, demonstrated promising monotherapy clinical activity in patients with advanced...

CMPX : 2.02 (-1.46%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Compass Therapeutics, Inc. - CMPX

NEW YORK , May 21, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Compass Therapeutics, Inc. ("Compass" or the "Company") (NASDAQ: CMPX). Such investors are...

CMPX : 2.02 (-1.46%)
Compass Therapeutics to Participate in Upcoming May Investor Events

BOSTON, May 12, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to...

CMPX : 2.02 (-1.46%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Compass Therapeutics, Inc. - CMPX

NEW YORK , May 7, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Compass Therapeutics, Inc. ("Compass" or the "Company") (NASDAQ: CMPX).  Such investors are...

CMPX : 2.02 (-1.46%)
Compass Therapeutics Reports 2026 First Quarter Financial Results and Provides Corporate Update 

As recently announced, tovecimig (DLL4 x VEGF-A bispecific antibody) in combination with paclitaxel demonstrated a highly statistically significant improvement in progression-free survival (PFS) versus...

CMPX : 2.02 (-1.46%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Compass Therapeutics, Inc. - CMPX

NEW YORK , April 30, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Compass Therapeutics, Inc. ("Compass" or the "Company") (NASDAQ: CMPX).  Such investors...

CMPX : 2.02 (-1.46%)
Tovecimig Demonstrates Statistically Significant Benefit in COMPANION-002 Randomized Phase 2/3 Study in Patients with Biliary Tract Cancer

Tovecimig (a DLL4 x VEGF-A bispecific antibody) in combination with paclitaxel demonstrated a highly statistically significant improvement versus paclitaxel alone in the key secondary endpoint of median...

CMPX : 2.02 (-1.46%)
Compass Therapeutics to Announce Topline Secondary Endpoints from the Phase 2/3 COMPANION-002 Study of Tovecimig in Patients with Biliary Tract Cancer

Webcast scheduled for Monday, April 27, 2026 at 8:00am ET. BOSTON, April 24, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical...

CMPX : 2.02 (-1.46%)

Business Summary

Compass Therapeutics Inc. is a clinical-stage biopharmaceutical company developing proprietary antibody therapeutics intended to engage the immune system to treat both solid tumors and hematologic malignancies. The company's lead product candidate includes CTX-471. Compass Therapeutics Inc. is based...

See More

Key Turning Points

3rd Resistance Point 2.22
2nd Resistance Point 2.17
1st Resistance Point 2.10
Last Price 2.02
1st Support Level 1.97
2nd Support Level 1.92
3rd Support Level 1.85

See More

52-Week High 6.88
Fibonacci 61.8% 4.87
Fibonacci 50% 4.24
Fibonacci 38.2% 3.62
Last Price 2.02
52-Week Low 1.61

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.